Cargando…
A randomized clinical trial of lipid metabolism modulation with fenofibrate for acute coronavirus disease 2019
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cytotoxicity may involve inhibition of peroxisome proliferator-activated receptor alpha. Fenofibrate activates peroxisome proliferator-activated receptor alpha and inhibits SARS-CoV-2 replication in vitro. Whether fenofibrate can be used t...
Ejemplares similares
-
A Randomized Trial of Lipid Metabolism Modulation with Fenofibrate for Acute Coronavirus Disease 2019
por: Chirinos, Julio, et al.
Publicado: (2022) -
COVID-19: Second Wave or Multiple Peaks, Natural Herd Immunity or Vaccine – We Should be Prepared
por: Moghnieh, Rima, et al.
Publicado: (2020) -
Parity and diabetes risk among hispanic women from Colombia: cross-sectional evidence
por: Cure, Pablo, et al.
Publicado: (2015) -
Alpha-lipoic acid may protect patients with diabetes against COVID-19 infection
por: Cure, Erkan, et al.
Publicado: (2020) -
COVID-19 May Predispose to Thrombosis by Affecting Both Vascular Endothelium and Platelets
por: Cure, Erkan, et al.
Publicado: (2020)